Par Drugs And Chemicals Ltd Share Price Today

Par Drugs And Chemicals Ltd. Share Price

Overview

Par Drugs And Chemicals Ltd. share price is currently ₹104.49, up by ₹0.40 (0.38%) from its previous closing price of ₹104.09. The share price has declined -23.47% over the past month and gained 3.98% over the past year. The stock's 52-week low and high are ₹76.93 and ₹178.64, respectively. Par Drugs And Chemicals Ltd. has a market capitalisation of ₹ 130.00 Cr. The share price was last updated on 23 Oct 2026, 03:29 PM IST.

Neha

23 Oct • 10:41 AM · SEBI-Registered Analyst

Market Crash Ya Mauka? Kaun Se Sectors Ko Fayda, Kise Nuksan

Stock market kyun gir raha hai? Crude oil $110 ke paar, Nifty recent high se ~10% neeche (24,800 → 22,200), smallcap ek din mein 2.4% gira. Is video mein data ke saath samjhiye: crude oil ka India par asar, kaun se sectors ko nuksaan (OMC, paint, airline, tyre) aur kise fayda (oil producers, IT), 2020 aur 2022 ke crash se seekh, aur ek investor ko abhi kya karna chahiye.

GROWW

⏱️ CHAPTERS 00:00 Crude $110, Nifty -10%: Crash Ya Mauka? 00:36 Market Kyun Gir Raha Hai 01:25 Crude Ka India Par Asar (Import, Rupee, Inflation, EMI) 02:05 Kis Sector Ko Nuksaan 02:50 Kis Sector Ko Fayda 03:22 History Se Seekh: 2020 & 2022 04:01 Investor Abhi Kya Kare: 5 Tips 04:44 Aapka Portfolio Kitna Gira? 📊 KEY POINTS • Brent crude $110+ (US–Iran tension, Saudi Aramco drone attack) • Nifty ~24,800 → ~22,200 (~10% fall) • Hang Seng -2.8%, Kospi -2.7%, Nikkei -1.7% • India imports ~85% of its crude oil • RBI repo rate 5.25% → 5.5% (7 Oct 2026) 💬 Comment karein: is girawat mein aap HOLD, ADD ya EXIT kar rahe ho? 👩‍💼 Neha Gupta | SEBI Registered Research Analyst | INH000016542 📞 8799766762 ⚠️ DISCLAIMER: Yeh video sirf educational purpose ke liye hai. Yeh kisi bhi stock ya sector ko buy, sell ya hold karne ki salah nahi hai. Market investments are subject to market risks. Investment se pehle apni research karein aur apna risk profile dekhein.

Saurabh Tyagi--Clovek,Advisory

22 Oct • 9:58 PM · SEBI-Registered Analyst

CreditAccess Grameen targets 20-25% AUM growth in FY27

CREDITACC

FY27 ROA guidance increased to 5.2%-5.8%, ROE to 21.0%-24.0%. Growth Targets: AUM growth guidance maintained at 20%-25% for FY27. Strategic Focus: Accelerating customer acquisition with target of 100,000+ new borrowers monthly in H2 FY27. Borrowing Costs: Average borrowing cost expected between 9.2%-9.3% for remainder of FY27. Challenges: Environmental impacts increased PAR temporarily; regulatory risks from insurance commission changes expected to affect ROA by 25-30 bps. Large PAT uplift (299% YoY) shows strong operating leverage and material earnings recovery versus prior year. AUM growth near 19.5% YoY with management targeting 20–25% implies continued scale-driven revenue growth potential. Management raised margins (NIM guidance 14.4–14.7%) and lowered cost-to-income guidance, implying higher core profitability ahead.

Neha

21 Oct • 10:40 AM · SEBI-Registered Analyst

HAL Order Book ₹2.54 Lakh Cr, Phir Bhi Tejas Delivery

HAL ke paas 8 SAAL ka kaam already booked! ✈️ Par bada order book = paisa pakka? NAHI! 👇 📦 Order book: ₹2.54 lakh crore (March 2026)

HFCL

💰 FY26 revenue: ₹32,250 crore 📊 Order book = ~7.9x saal bhar ki revenue ✈️ Isme 97 Tejas Mk1A ka ₹62,370 cr ka order shamil ⚠️ Wajah: Tejas Mk1A mein lagne wala GE F404 engine time par nahi aa raha. FY26 mein 11 engines ka wada tha, mile sirf 6. Pehla jet March 2024 mein milna tha, ab HAL ka plan March 2027 tak 10 jets dene ka hai. ➡️ Seekh: order book sirf kaam batata hai, paisa delivery se aata hai. Execution aur supply chain zaroor dekho. 💬 Aapke hisaab se order book zyada important hai ya execution? 👇 📲 Free Telegram par roz ke market notes: link bio mein Neha Gupta | SEBI Registered Research Analyst | Reg. No. INH000016542 ⚠️ Educational purposes only. Not investment advice. Investments in securities are subject to market risks. #HAL #HALShare #TejasMk1A #OrderBook #DefenceStocks #HindustanAeronautics #StockMarketIndia #SEBIRegistered

Naveen Kumar

20 Oct • 3:19 AM · SEBI-Registered Analyst

Paras Healthcare company ipo valuation analysis

Paras Healthcare is launching its IPO between October 21 and 23 at a valuation of 7,500 crore rupees. Of the 1,400 crore rupees being raised, only 500 crore rupees will support the company, while 950 crore rupees constitute an exit for existing promoters and corporate investors. With a price-to-book ratio of approximately 8x post-IPO, the company is valued on par with established industry giants. While Paras Healthcare demonstrates strong revenue growth of 20 to 30 percent and is successfully expanding its bed capacity, the aggressive valuation leaves little room for upside for new retail investors. Significant debt reduction from IPO proceeds will improve net margins, but regulatory risks regarding healthcare pricing caps remain a critical concern. If government policy intervenes to limit profit margins, the company’s current high price-to-earnings multiple could collapse, causing a sharp decline in share price. Given the heavy exit of early-stage investors, the short-term outlook is cautious. Long-term potential exists due to aggressive hospital chain expansion, but current valuation multiples offer a poor margin of safety.

Shrikant Pandey

19 Oct • 12:43 PM · SEBI-Registered Analyst

CAPRI GLOBAL: To Issue $30 Mn Senior Secured Bonds

CGCL

- Capri Global Capital plans to issue up to 3,000 USD-denominated senior secured non-convertible bonds, with a face value of US$10,000 each, aggregating up to US$30 million. - The bonds will be issued at par through private placement to identified investors in dematerialised form. - The coupon will be 240 bps + 6-month CME Term SOFR, payable semi-annually. - The bonds will have a 36-month tenure and will be secured by a first-ranking pari-passu hypothecation charge over identified receivables. - The proposed bonds are planned to be listed on India International Exchange IFSC and/or NSE IFSC. - India International Depository IFSC is proposed to act as the registrar and transfer agent. Impact: Positive — The proposed US$30 million issuance diversifies Capri Global's funding sources and provides access to USD-denominated institutional funding through the IFSC market. However, as the bonds are secured against receivables and carry a floating-rate coupon, the key factors to monitor are funding cost, leverage and deployment of the raised capital.

Sunil Kotak

16 Oct • 8:42 AM · SEBI-Registered Analyst

HDFC Life posts 14% rise in Sept quarter profit

HDFCLIFE

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Key take away - Value of new business (VNB) margin expanded 20 basis points to 24.7% against 24.5% a year ago. One basis point is a hundredth of a percentage point. Value of new business grew 12% to ₹2,040 crore Mumbai: HDFC Life Insurance reported a 14% increase in standalone net profit to ₹508 crore for the September quarter, compared with ₹447 crore a year earlier, as premium income rose and the insurer expanded sales of non-participating (non-par) savings, annuity and protection products. Net premium income increased 16% to ₹21,727 crore from ₹18,777 crore in the corresponding quarter last year. Value of new business (VNB) margin expanded 20 basis points to 24.7% against 24.5% a year ago. One basis point is a hundredth of a percentage point. Value of new business grew 12% to ₹2,040 crore. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

Par Drugs And Chemicals Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Par Drugs And Chemicals Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Par Drugs And Chemicals Ltd.?

What is the market cap of Par Drugs And Chemicals Ltd.?

Should I buy Par Drugs And Chemicals Ltd. stock now?

What is the 52 week high and low of Par Drugs And Chemicals Ltd.?

Is the Par Drugs And Chemicals Ltd. stock good to buy?

Is Par Drugs And Chemicals Ltd. a good buy for the long term?

Is Par Drugs And Chemicals Ltd. overvalued or undervalued?

What is the PE and PB ratio of Par Drugs And Chemicals Ltd.?